Core Insights - BioHarvest Sciences Inc. has successfully progressed its CDMO contract with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, validating its Botanical Synthesis platform for developing active pharmaceutical compounds [1][4] Group 1: Contract Development and Manufacturing Organization (CDMO) Progress - Stage 1 of the contract, initiated in early 2024, involved sourcing plants to develop a compound for an approved drug product, which has now been completed successfully [2] - The successful completion of Stage 1 indicates that the research team isolated and multiplied the target plant cells using the proprietary Botanical Synthesis platform [2] - Stage 2 will focus on delivering sufficient biomass for testing and developing optimal growing conditions, leading to small and medium-scale production and eventually commercial volume production [3] Group 2: Company Statements and Future Outlook - The CEO of BioHarvest expressed excitement about advancing to Stage 2, highlighting the milestone as a validation of the platform's versatility and its potential to provide cost-effective alternatives to traditional sourcing methods [4] - The Chairman of the CDMO Division noted that Stage 1 carried the highest technical risk, and its successful completion demonstrates the platform's capability to address a wide range of molecule families, with Stage 2 expected to have a higher probability of success [4]

The market expects BioHarvest Sciences Inc. (BHST) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to ...

Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2024 Expressed in U.S. dollars in thousands TABLE OF CONTENTS | | Page | | --- | --- | | FINANCIAL STATEMENTS: | | | Unaudited Interim Condensed Consolidated Statements of Financial Position | 3 ...

BioHarvest Sciences Inc. 2 BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Six Months Ended June 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Six Months Ended June 30, 2024 Expressed in U.S. dollars in thousands TABLE OF CONTENTS | | Page | | --- | --- | | FINANCIAL STATEMENTS: | | | Unaudited Interim Condensed Consolidated Statements of Financi ...